Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia
September 18, 2024 07:00 ET
|
Engrail Therapeutics, Inc.
Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
March 19, 2024 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Major Depressive Disorder Market to Register Stunning Growth During the Forecast Period (2023–2032), Examines DelveInsight | Leading Companies - Otsuka, Sumitomo, COMPASS, Sage, Neurocrine, Boehringer Ingelheim, Janssen
November 16, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Major Depressive Disorder Market to Register Stunning Growth During the Forecast Period (2023–2032), Examines DelveInsight | Leading Companies -...
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)
October 09, 2023 08:30 ET
|
ABVC BioPharma, Inc.
The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage...
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
September 07, 2023 07:03 ET
|
Axsome Therapeutics, Inc.
Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with obstructive sleep apnea and narcolepsy NEW...
InvestmentPitch Media Video Discusses MindBio Therapeutics' Commencement of MB22001 Phase 2 Clinical Trial in World's First Take-Home Microdosing Study for Patients with Depression
August 25, 2023 06:00 ET
|
InvestmentPitch Media & MindBio Therapeutics
VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), an Australia-based biotech/biopharma company creating novel and emerging treatments for...
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 30, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with...
ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder
May 04, 2023 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
October 20, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week1-4 ...
Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of neuropsychiatric disorders
February 14, 2022 02:00 ET
|
Nexstim Oyj
Company Announcement, Inside Information, Helsinki, 14 February 2022, at 9 AM (EET) Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of...